Individuals with HIV who were resistant to all four antiretroviral drug classes experienced higher mortality than those who were not resistant, a difference primarily due to lower CD4 cell counts.
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results